ASH 2025: Myelofibrosis Roundup

1. Pelabresib shows promise in combination with ruxolitinib for myelofibrosis treatment. 2. MANIFEST-2 trial data shows significant spleen volume reduction. 3. Elritercept helps manage anemia in high-risk myelofibrosis patients. 4. Ruxolitinib has shown long-term effectiveness. 5. Stem cell transplant remains the only curative option for eligible patients. 6. Ongoing studies validate the role of combination therapies in this patient population.